Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 6/20 | 0.39 |
| ▸ | RORC | P51449 | 6/20 | 0.39 |
| ▸ | RORB | Q92753 | 6/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 8/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236922 | 0.96 | PTGDR2 (0.38) | RORARORCRORBPTGDR2PGR | |
| SCHEMBL5238249 | 0.89 | TSHR (0.38) | RORARORCRORBPTGDR2PGR | |
| SCHEMBL5238745 | 0.88 | RORA (0.40) | RORARORCRORBPGRTSHR | |
| SCHEMBL5232925 | 0.88 | TSHR (0.45) | RORARORCRORBPGRTSHR | |
| SCHEMBL5234959 | 0.87 | PRMT5 (0.39) | TSHRPTK2BDPP4 | |
| SCHEMBL5236649 | 0.87 | MEN1 (0.40) | RORARORCRORBPGRTSHR | |
| SCHEMBL5235940 | 0.87 | ALDH1A1 (0.40) | TSHRPTK2BDPP4 | |
| SCHEMBL5237827 | 0.86 | TSHR (0.42) | TSHRPTK2BMETAP2 | |
| SCHEMBL5237497 | 0.85 | TSHR (0.38) | PTGDR2TSHRPTK2BDPP4METAP2 | |
| SCHEMBL5239302 | 0.85 | TSHR (0.39) | TSHRPTK2BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
| WO-2002062764-A9 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | RORA 2682/4885RORC 2671/4885RORB 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.